Compare Merck & Co., Inc. (MRK) vs Tesla, Inc. (TSLA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Tesla, Inc. — how do they compare? Merck & Co., Inc. trades at $126.01 (market cap $307.25B), while Tesla, Inc. trades at $379.29 (market cap $1.39T). The key difference: Tesla, Inc. is far larger — about 4.5× Merck & Co., Inc.'s market cap, and Merck & Co., Inc. pays a 2.73% dividend while Tesla, Inc. pays none. Which is the better fit depends on your goals.
| MRK | TSLA | |
|---|---|---|
Market Cap | $307.25B | $1.39T |
Sector | Health | Consumer Cyclical |
52-Week High | $129.52 | $489.88 |
52-Week Low | $77.60 | $302.63 |
Enterprise Value | $350.66B | $1.36T |
Dividend Yield | 2.73% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $126.27, down 0.96% on the day, with a neutral technical signal and strong fundamentals including a net income margin of 13.59% and ROE of 18.97%. Recent earnings beats and the acquisition of Terns Pharmaceuticals for approximately $6.7 billion highlight strategic growth initiatives. The stock is supported by a consensus analyst price target of $137.30, indicating potential upside from current levels.
The outlook for Merck is positive, driven by robust profitability, strategic acquisitions, and analyst confidence. Key risks include rising debt levels, with debt-to-asset ratio increasing to 36.06% in 2025, and competitive pressures in the oncology space. Investors should weigh strong cash flow generation against execution risks in integrating recent acquisitions.
Tesla (TSLA) trades at $378.88, down 0.51% on the day, as the stock faces technical bearish signals despite recent earnings beats. The company shows mixed fundamentals with revenue declining to $94.83B in 2025 and net income margin compressing to 3.95%, while valuation multiples remain elevated with a P/E of 339.06. Recent news highlights Tesla's strategic pivot toward robotics, AI, and energy growth amid a slowing auto business, with regulatory approval for driver-assistance software in Europe providing a potential catalyst.
Tesla's investment case balances high-growth potential in autonomy and energy against near-term execution risks and rich valuations. The consensus price target of $409.26 suggests modest upside, but investors face headwinds from competitive pressures and margin compression. The stock's trajectory will likely hinge on successful commercialization of new technologies and improved automotive profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Tesla, Inc.
Tesla Inc. designs, manufactures, and sells high-performance electric vehicles and electric vehicle powertrain components. The Company owns its sales and service network and sells electric power train components to other automobile manufacturers. Tesla serves customers worldwide.
Read more on TSLA →
